drugset / Trial / NCT06940440
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.
Timeline
- Start
- 2025-10
- Primary completion
- 2026-05-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IFx-Hu2.0 | Vaccine | 0.1 mg | Other |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |